OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Women in Oncology: Leukemia Therapies in Humans, for Humans

July 24th 2022

Judith Karp, MD, Azra Raza, MD, and Michelle M. Le Beau, PhD, discuss their proudest career accomplishments, including the investigation of potential treatments using a patient’s first cancerous cell, advances in cytogenetics, and a rational design for clinical trials involving cell cytokinetics..

Women in Oncology: Finding Strength and Support in Community

July 24th 2022

Judith Karp, MD, Azra Raza, MD,, and Michelle M. Le Beau, PhD, discuss how their gender has shaped their professional lives, from working as some of the only female clinical faculty at their institutions to being compared to their male colleagues and denied opportunities when working independently from men.

Dr. Adashek on Targeting Molecular Alterations to Treat Multiple Tumor Types

July 22nd 2022

Jacob J. Adashek, DO, discusses how targeting molecular alterations is key for treating multiple types of cancer.

Dr. Brody on Second-Line CAR T-cell Therapy in DLBCL

July 22nd 2022

Joshua Brody, MD, discusses the significance of CAR T-cell therapies being used in earlier treatment lines in patients with diffuse large B-cell lymphoma who relapse within their first year of receiving chemotherapy.

Dr. D’Angelo on Emerging Therapies in DLBCL

July 21st 2022

Christopher R. D’Angelo, MD, discusses emerging therapies in diffuse large B-cell lymphoma.

Dr. Porter on the 3-Year Follow-Up Data From the CheckMate-9LA Trial in NSCLC

July 21st 2022

Jason Porter, MD, discusses the 3-year follow-up data from the phase 3 CheckMate-9LA trial done in patients with metastatic non–small cell lung cancer.

Dr. Ready on the Practice Implications of Nivolumab/Ipilimumab in NSCLC

July 21st 2022

Neal Edward Ready, MD, PhD, discusses the practice implications of nivolumab plus ipilimumab in patients with metastatic non–small cell lung cancer.

Dr. Barba on the Safety of Obecabtagene Autoleucel in Relapsed/Refractory B-ALL

July 21st 2022

Pere Barba, MD, PhD, discusses the safety of obecabtagene autoleucel in patients with relapsed or refractory B-cell acute lymphoblastic leukemia.

Dr. Phillips on p53 Mutations in MCL

July 20th 2022

Tycel Jovelle Phillips, MD, discusses the role of p53 mutations in the outcomes of patients with mantle cell lymphoma.

Dr. Kallam on the Role of BTK and PI3K Inhibitors in CNS Lymphoma

July 20th 2022

Avyakta Kallam, MBBS, discusses the role of BTK and PI3K inhibitors in the treatment of patients with central nervous system lymphoma.

Dr. Mehta-Shah on the Variations of the CHOP Regimen in PTCL

July 20th 2022

Neha Mehta-Shah, MD, MSCI, discusses variations of CHOP-based chemotherapy in peripheral T-cell lymphoma.

Dr. Kahl on the Evolving Standard of Care in MCL

July 20th 2022

Brad S. Kahl, MD, discusses current best practices for the treatment of older patients with mantle cell lymphoma, as well as where the treatment paradigm might lead in the future.

Dr. Strickler on the Efficacy of Tucatinib/Trastuzumab in HER2+ Colorectal Cancer

July 16th 2022

John H. Strickler, MD, discusses the efficacy of tucatinib plus trastuzumab in HER2-positive colorectal cancer.

Dr. Shitara on the Rationale for the DESTINY-Gastric04 Trial in HER2+ Gastric Cancers

July 16th 2022

Kohei Shitara, MD, discusses the rationale for the phase 3 DESTINY-Gastric04 trial in patients with HER2-positive gastric cancer or gastro-esophageal junction adenocarcinoma.

Dr. Brahmer on the Examination of Nemvaleukin Alfa in Solid Tumors

July 16th 2022

Julie R. Brahmer, MD, MSc, discusses the examination of nemvaleukin alfa in solid tumors.

Dr. Waks on the Continued Evaluation of Immunotherapy in HER2+ Breast Cancer

July 14th 2022

Adrienne G. Waks, MD, discusses the continued evaluation of immunotherapy in HER2-positive breast cancer.

Dr. Porcu on the Need for Diverse Representation in Clinical Trials

July 14th 2022

Pierluigi Porcu, MD, discusses the need for diverse representation in clinical trials.

Dr. Kalinsky on Ovarian Function Suppression and Chemotherapy in HR–Positive Breast Cancer

July 14th 2022

Kevin Kalinsky, MD, MS, discusses the relationship between ovarian function suppression and chemotherapy benefits in premenopausal patients with HR–positive breast cancer.

Dr. Brahmer on the 5-Year Data for Nivolumab/Ipilimumab in NSCLC

July 14th 2022

Julie R. Brahmer, MD, MSc, discusses the significance of the long-term survival data of nivolumab plus ipilimumab seen in the phase 3 CheckMate-227 trial in patients with metastatic non–small cell lung cancer.

Dr. Paz-Ares on Nivolumab/Ipilimumab Plus Chemotherapy in NSCLC

July 14th 2022

Luis G. Paz-Ares, MD, PhD, discuses the importance of nivolumab plus ipilimumab in the treatment of patients with metastatic non–small cell lung cancer.